Irinotecan (hydrochloride trihydrate)

Irinotecan (hydrochloride trihydrate)

• CAS Number: 136572-09-3
• UNSPSC Description: Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity[1].
• Target Antigen: Autophagy; Topoisomerase
• Type: Reference compound
• Related Pathways: Autophagy;Cell Cycle/DNA Damage
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/irinotecan-hydrochloride-trihydrate.html
• Solubility: DMSO : 50 mg/mL (ultrasonic)|Ethanol : 3.33 mg/mL (ultrasonic)|H2O : 1.52 mg/mL (ultrasonic;warming)
• Smiles: [H]Cl.O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3.O.O.O
• Molecular Weight: 677.18
• References & Citations: [1]Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26.|[2]Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30.|[3]Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5.J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Acta Pharm Sin B. 2023 Dec 30.|Apoptosis. 2016 Feb;21(2):130-42. |Biochem Pharmacol. 2023 Aug 25;115752.|Biochim Biophys Acta Mol Basis Dis. 2024 Aug 16:167471.|Biomaterials. 16 September 2022.|Biomed Pharmacother. 2020 Aug;128:110262.|Biomed Pharmacother. 2023 Apr 25;163:114751.|bioRxiv. 2019 Dec.|Cancer Lett. 2022 Nov 30;216028.|Cell Biosci. 2023 Nov 25;13(1):215.|Cell Death Dis. 2019 Nov 25;10(12):887. |Cell Death Dis. 2024 Jun 15;15(6):417.|Cell Discov. 2022 Sep 14;8(1):92.|Cell Rep Med. 2023 Jan 10;100911.|Cell Rep Med. 2024 Mar 19;5(3):101468.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Cell. 2022 Sep 1;185(18):3356-3374.e22.|Clin Cancer Res. 2023 Sep 19.|EBioMedicine. 2023 May 9;92:104594.|Eur J Pharm Biopharm. 2022 Jan 5;S0939-6411(21)00272-1.|Eur J Pharmacol. 2023 Apr 11;949:175718.|Gastroenterology. 2021 Nov;161(5):1601-1614.e23.|Gene. 2019 Mar 10;688:1-6. |Genome Med. 2016 Oct 31;8(1):116.|Heliyon. 2023 Apr 21.|INT J PHARMACEUT. 2020 May.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Pharm Pharmacol. 2023 Mar 1;rgad007.|Life Sci. 2019 Aug 15;231:116529. |Lung Cancer. 2023 Mar 8;178:237-246.|Mol Biol Cell. 2023 Mar 29;mbcE22110518.|Mol Cancer Ther. 2021 Oct 28.|Mol Cancer. 2024 Apr 4;23(1):70.|Mol Cancer Res. 2020 Mar;18(3):414-423.|Patent. US20210009719A1.|Pharmacol Res. 2021 Jan;163:105232.|PLoS Biol. 2022 Feb 24;20(2):e3001517.|PLoS Pathog. 2020 Mar 24;16(3):e1008429.|Redox Biol. 2024 May 23:73:103207.|Signal Transduct Target Ther. 2021 May 28;6(1):188.|Theranostics. 2019 May 31;9(13):3732-3753.|Apoptosis. 2019 Apr;24(3-4):312-325.|Cancers (Basel). 2023 Sep 6, 15(18), 4442.|Front Immunol. 2018 Jan 5;8:1919.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Ruperto Carola University Heidelberg. Natural Sciences and Mathematics. 18 March 2022.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched